PlainPharmaWatch

CMS Open Payments · Program Year 2024

Octapharma USA, Inc.

Octapharma USA, Inc. reported $4,421,793.52 across General Payments, Research, and Ownership to 5,207 physicians and teaching hospitals across 5,449 transactions.

See the rankings → How this is sourced
$4.4M
All-tracks total
5,449
Transactions
5,207
Recipients
+$620.7K
General Payments vs PY2023

Octapharma USA, Inc. reported $4,421,793.52 across all CMS Open Payments tracks (General + Research + Ownership) to 5,207 physicians and teaching hospitals in Program Year 2024 - ranking #292 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,023,395.55, averaging $849.20 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer octapharma-usa-inc Octapharma USA, Inc.

$4.4M · #292/1,925 · 0.0% industry · PY2024

  • TOT $4.4M
  • RANK #292
  • SHARE 0.0%
  • TXN 5,449
  • RCP 5,207
  • CAT 6
  • GEN $1.0M
  • ΔGEN +$620.7K
  • TOP1 13.9%
  • PY 2024

Volume peers

Nearest volume peer: Salix Pharmaceuticals, a division of Bausch Health US, LLC ($4.4M)

bluebird bio, Inc.$4.5MNovocure Inc.$4.5MOctapharma USA, Inc. (this)$4.4MSalix Pharmaceuticals, a div…$4.4MExact Sciences Corporation$4.4M
All-tracks payment totals near Octapharma USA, Inc. (CMS Open Payments PY2024)

Octapharma USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Octapharma USA, Inc.'s CMS-reported General Payments increased by $620.7K (+154.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: OCTAPHARMA USA, INC.PY2023: OCTAPHARMA USA, INC.PY2024: Octapharma USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$402.6KPY2024$1.0M
PY2023
$402,646.73
PY2024
$1,023,395.55

What the Data Shows for Octapharma USA, Inc.

Octapharma USA, Inc. ranks #292 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $4,421,793.52 across 5,449 transactions to 5,207 physicians and teaching hospitals - $811.49 per transaction and $849.20 per recipient on average.

7 transactions worth $359.5K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 35.1% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Octapharma USA, Inc. made 6 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $359.5K, 35.1% of General Payments.

Octapharma USA, Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (35.1%), Travel and Lodging (25.2%), and Honoraria (18.0%). The remaining 3 categories make up 21.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Octapharma USA, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Compensation for Services…$359.5K2. Travel and Lodging$257.4K3. Honoraria$184.4K4. Food and Beverage$132.9K5. Grant$87.5K6. Consulting Fee$1.7K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $359.5K 7
Travel and Lodging $257.4K 187
Honoraria $184.4K 65
Food and Beverage $132.9K 4,917
Grant $87.5K 4
Consulting Fee $1.7K 27

Recipient Concentration in General Payments

The five largest recipient relationships account for $409,273.08 (40.0%) of $1,023,395.55 in this company's General Payments records across 3,055 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Octapharma USA, Inc.

The five named recipients with the highest reported General Payments from this company

Isaac Melamed$142.3KLawrence Steinman$114.1KMazen Dimachkie$57.5KRobert Sidonio$50.3KJennifer Frankovich$45.0K
  1. 1

    Isaac Melamed

    $142,338.49 across 15 reported transactions

  2. 2

    Lawrence Steinman

    $114,105.00 across 1 reported transactions

  3. 3

    Mazen Dimachkie

    $57,500.00 across 3 reported transactions

  4. 4

    Robert Sidonio

    $50,329.59 across 15 reported transactions

  5. 5

    Jennifer Frankovich

    $45,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Octapharma USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Octapharma USA, Inc..

Alliance Medical

HHI 480

Kyocera Medical Technologies, Inc.

HHI 480

International Life Sciences

HHI 481

GC America Inc.

HHI 479

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Octapharma USA, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Octapharma USA, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.